The SENS Foundation, a charity dedicated to accelerating the development of rejuvenation biotechnology was given the opportunity recently to fund a research project towards therapies in the Genetic Amyloidosis field.
More specifically, the project will focus on therapies for ‘Senile’ or ‘Age-Related’ Systemic Amyloidosis (SSA) caused by aggregated wild-type ‘transthyretin’ (TTR), and isolated atrial amyloidosis (IAA), caused by aggregated atrial natriureptide (ANP). These cardiac amyloidoses are poised to become a widespread medical problem for the global aging population. The deposits of abnormal protein or transthyretin affect the heart tissue, resulting in decreased heart function and deterioration.
The prevalence of cardiac amyloidoses is shocking among the elderly and instances of this disorder are rising rapidly. Cases are now beginning to increase among the “Baby Boomer” generation in the United States and the incidence and severity of the disease will certainly rise further as this group ages.
